MedTrace Logo

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

NCT07712536 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-07-17

No results posted yet for this study

Summary

To evaluate the population pharmacokinetic characteristics of QY201 Tablets in adolescent participants with moderate to severe atopic dermatitis (AD).

Conditions

  • Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)

Interventions

DRUG

QY201 Tablets（10mg）

10 mg twice daily for 28 consecutive days

DRUG

QY201 Tablets（20mg）

20 mg twice daily for 28 consecutive days

Sponsors & Collaborators

  • E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-04
Primary Completion
2025-12-19
Completion
2025-12-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07712536 on ClinicalTrials.gov